Navigation Links
AutoImmune Inc. Reports 2008 Second Quarter Financial Results
Date:8/7/2008

t are not strictly historical are forward-looking statements including statements about clinical trials and studies and future sales, royalties and revenue. You can identify these forward-looking statements because they involve our expectations, beliefs, projections, anticipations or other characterizations of future events or circumstances. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements as a result of any number of factors. These factors include, but are not limited to the uncertainties of clinical trial results, the Company's dependence on third parties for licensing revenue, and the risks of technological change and competition. These factors are more fully discussed, as are other factors, in the Company's most recent Annual Report on Form 10-KSB filed with the Securities and Exchange Commission in the section entitled "Risk Factors."

- Financial Chart Follows -

AUTOIMMUNE INC.

STATEMENT OF OPERATIONS

(Unaudited)

Three months ended June 30, Six months ended June 30,

2007 2008 2007 2008

Revenue $63,000 $101,000 $160,000 $168,000

Costs and expenses:

Cost of product

revenue 2,000 16,000 11,000 28,000

Research and

development 58,000 48,000 88,000 90,000

Selling, general

and administrative 184,000 181,000 369,000 386,000

Total costs

and expenses 244,000 245,000 468,000 504,000

Interest income 113,000 60,000 223,000 144,000

Minority intere
'/>"/>

SOURCE AutoImmune Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
2. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes - Correction
3. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes
4. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
5. Isis Reports Financial Results and Highlights for Second Quarter of 2008
6. Barr Reports Second Quarter 2008 GAAP Earnings of $0.52 Per Share; Adjusted Earnings of $0.64 Per Share
7. PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results
8. Caliper Life Sciences Reports Second Quarter 2008 Results
9. Watson Pharmaceuticals Reports Second Quarter 2008 Results
10. EntreMed Reports Second Quarter 2008 Financial Results
11. Transgenomic Reports Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... , March 25, 2015 /PRNewswire/ - SQI Diagnostics Inc. ... that, as a result of recent discussions with certain ... shares of the Company, after dealing with certain matters ... special meeting of shareholders on March 26, 2015 (the ... the election of directors will take place when the ...
(Date:3/25/2015)... 25, 2015 Accelovance, a therapeutically focused contract ... "Best Contract Research Organization" at the upcoming Vaccine Industry ... This is the eighth consecutive year ... award, winning for "Best Contract Research Organization" in 2009, ... in 2013. "We,re excited to be a ...
(Date:3/25/2015)... IL (PRWEB) March 25, 2015 Having ... in the latter part of 2014, ITRA Global proudly ... Global, the International Tenant Representative Alliance, based in the ... to representing tenants and occupiers of commercial real estate. ... estate advisory firm in Poland that exclusively advises occupiers ...
(Date:3/25/2015)... , March 25, 2015  18 piglets born ... intense research by scientists in the College of Agriculture ... represent a breakthrough in the field of genetic ... the Department of Animal & Avian Sciences (ANSC) and ... ANSC, successfully produced genome-edited pigs using a recently ...
Breaking Biology Technology:SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 2SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 4SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 5Accelovance Nominated for 2015 Vaccine Industry Excellence (ViE) Awards 2International Organization Expands its Global Reach to Warsaw, Poland 2University of Maryland Researchers Successfully Produce Genome-edited Pigs Using Revolutionary Technology 2
... NEW YORK, April 16 NexGenix Pharmaceuticals, presented,data ... Annual Meeting of the AACR,in San Diego today. ... on NXD30001, one of several novel, radicicol-based,Hsp90 inhibitors ... in breast cancer tumor xenograft models,without evidence for ...
... April 16 Kosan Biosciences,Incorporated (Nasdaq: KOSN ... inhibitors demonstrating a high degree of target,specificity, strong ... tumor,tissue and significant antitumor activity and safety in ... protein chaperone that acts to stabilize and/or activate ...
... ROCKVILLE, Md., April 16 The Board of ... that Dr. Danong Chen has,been elected as the ... Chen,was previously the President and CEO of Tanox ... by Genentech in 2007.,Previously Dr. Chen was Vice-President ...
Cached Biology Technology:NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect 2NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect 3Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR 2Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR 3Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR 4Danong Chen appointed CEO of Theranostics Health 2
(Date:3/16/2015)... HANOVER, Germany , March 16, 2015 /PRNewswire/ ... DERMALOG Identification Systems GmbH will present groundbreaking innovations ... Hanover, Germany . ... DERMALOG,s latest biometric innovation is well at ... the next generation e-gate made in ...
(Date:3/12/2015)... March 12, 2015 Beta ... identity and access management (IAM) solution for a ... With Beta System,s new IAM package, customers benefit ... gleaned from multiple IAM implementations across different industries. ... as well as any necessary services and consulting. ...
(Date:3/11/2015)...   The Sync Project™ today announced ... and harness music to improve health. The platform ... measurements of physiology, enabling the study of the ... populations. It is designed for medical and health ... studies and accelerate the discovery of the clinical ...
Breaking Biology News(10 mins):DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3
... of Chicago Celiac Disease Center is hosting the 15th ... in Chicago. The symposium is the largest celiac disease ... which follows the 2011 conference in Oslo, Norway, is ... since 2006. The Chicago meeting seeks to address ...
... a continued increase in the proportion of its journal titles indexed ... JCR ), with 1,192 (approximately 77%) titles now indexed, up from ... largest share of journals in 50 categories. In the ... rank increased by 19% (4) and the number of Wiley titles ...
... Cancer Research Group (ACRG), an independent, not-for-profit company in ... The University of Hong Kong (HKU), jointly announced the ... in hepatocellular carcinoma (HCC), one of the most deadly ... . The study provides new insights into potential therapeutic ...
Cached Biology News:UChicago Celiac Disease Center to host international symposium 2Wiley announces increase in Impact Factors 2Wiley announces increase in Impact Factors 3Wiley announces increase in Impact Factors 4Wiley announces increase in Impact Factors 5Wiley announces increase in Impact Factors 6ACRG and BGI report new evidence for the genetic bases of liver cancer 2
... atoms at the 9, 10, 12, and 13 ... internal standard for the quantification of 13(S)-HODE by ... incubation of linoleic acid with plant and mammalian ... adhesion of tumor cells to the endothelium at ...
...
...
...
Biology Products: